|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/20/21 AbbVie Inc. 8-K:7,9 4/16/21 12:322K Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 54K 2: EX-99.1 Miscellaneous Exhibit HTML 9K 8: R1 Cover HTML 75K 10: XML IDEA XML File -- Filing Summary XML 12K 7: XML XBRL Instance -- tm2113328d1_8k_htm XML 44K 9: EXCEL IDEA Workbook of Financial Reports XLSX 7K 4: EX-101.DEF XBRL Definitions -- abbv-20210416_def XML 87K 5: EX-101.LAB XBRL Labels -- abbv-20210416_lab XML 129K 6: EX-101.PRE XBRL Presentations -- abbv-20210416_pre XML 83K 3: EX-101.SCH XBRL Schema -- abbv-20210416 XSD 19K 11: JSON XBRL Instance as JSON Data -- MetaLinks 30± 39K 12: ZIP XBRL Zipped Folder -- 0001104659-21-052229-xbrl Zip 19K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i April 16, 2021
(Exact Name of Registrant as Specified in its Charter)
_______________________________________________
| i Delaware | i 001-35565 | i 32-0375147 | ||
| (State or other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
_______________________________________________
i North Chicago, i Illinois i 60064-6400
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: ( i 847) i 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| i ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| i ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| i ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| i ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
C:
| Item 7.01 | Regulation FD Disclosure. |
On April 16, 2021, AbbVie Inc. delivered a notice of redemption to the holders of its 0.500% Senior Notes due 2021 (the “Notes”), announcing the redemption on May 1, 2021 of all of its outstanding Notes. A copy of the notice is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein in its entirety.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. |
Exhibit | |
| 99.1 | Notice of Redemption dated April 16, 2021. | |
| 104 | The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). | |
C:
C: 2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ABBVIE INC. | ||
| Date: April 20, 2021 | By: | /s/ Robert A. Michael |
| Name: Robert A. Michael | ||
| Title: Executive Vice President, Chief Financial Officer | ||
C:
3
C:
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 5/1/21 | None on these Dates | |||
| Filed on: | 4/20/21 | |||
| For Period end: | 4/16/21 | |||
| List all Filings | ||||